Third Annual Meeting of Spoke 3 on RNA-Based Therapies for Neurological Disorders in Naples

7 October 2025, Naples — Underscoring Italy’s growing leadership in RNA-based medicine, the National Center celebrates Spoke 3 third annual meeting from October 5–7, 2025, in Naples. The focus: innovative RNA-based therapies for neurological disorders, from neurodevelopmental conditions to neurodegeneration and stroke.

Coordinated by the Istituto Italiano di Tecnologia (IIT), Spoke 3 convenes over 150 scientists from across 15 universities, 2 national research institutes, 2 clinical hospitals, and 3 biotech firms, forming a dynamic network committed to translating RNA biology into real-world therapies.

The three-day event is one of Europe’s most comprehensive conferences dedicated exclusively to RNA technologies in neuroscience. The scientific program covers key topics including RNA metabolism, gene regulation, expanded repeat disorders, retinal disease, and stroke therapies.

Cutting-Edge Italian Research in the Spotlight

Italian researchers from institutions including University of Napoli Federico II, University of Milano, University of Padua, CNR, and NEUROMED will present advances in gene editing, circRNA therapeutics, and nanomedicine for treating ALS, Huntington’s disease, and retinitis pigmentosa.

Key presentations:

• Prof. Marta Biagioli (UniTN) on therapeutic insights from circHTT in Huntington’s disease,
• Prof. Velia Siciliano (IIT) on RNA-based bioengineering approaches,
• Dr. Vittorio Maglione (NEUROMED) on nanoparticle-mediated delivery of RNA in neurodegeneration.

Collaboration and Translation: A Central Goal

The program emphasizes translational impact and collaboration, offering poster sessions, open discussions, and matchmaking opportunities for biotech and clinical researchers. It aims to accelerate bench-to-bedside transitions for RNA therapeutics in CNS diseases.

The event is part of Italy’s broader national strategy in biotech and RNA technologies, spearheaded by the National Recovery and Resilience Plan (PNRR), and aligns with international efforts to combat neurodegenerative and developmental disorders.